TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

BMC Cancer · 2014 · PMC4091674 · PMID 24884504

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = 0.06so close (0.05 < p ≤ 0.1)

We were, however, able to identify a subgroup of patients that derived clinically meaningful benefit from combination chemotherapy as compared to single agent chemotherapy using TIMP-1 immunoreactivity although the results did not reach statistical significance (P = 0.06).

also in 111,027 other papers

borderline significantno p-value reported

Additionally, a borderline significant interaction for OS was observed between TIMP-1 status and benefit from GD compared to D (P interaction = 0.06) such that median OS increased by nine months for TIMP-1 negative patients receiving GD.

also in 11,409 other papers

borderline significanceno p-value reported

However, the test for interaction between TIMP-1 status and treatment did only reach borderline significance.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.